You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameHydroflumethiazide
Accession NumberDB00774  (APRD01020)
TypeSmall Molecule
GroupsApproved
DescriptionA thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822)
Structure
Thumb
Synonyms
Dihydroflumethazide
Hidroflumetiazid
Hidroflumetiazida
Hydrofluméthiazide
Hydroflumethiazide
Hydroflumethiazidum
Idroflumetiazide
Metforylthiadiazin
Saluron
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
LeodrineLeo
SaluronShire
Brand mixturesNot Available
SaltsNot Available
Categories
UNII501CFL162R
CAS number135-09-1
WeightAverage: 331.292
Monoisotopic: 330.990831754
Chemical FormulaC8H8F3N3O4S2
InChI KeyInChIKey=DMDGGSIALPNSEE-UHFFFAOYSA-N
InChI
InChI=1S/C8H8F3N3O4S2/c9-8(10,11)4-1-5-7(2-6(4)19(12,15)16)20(17,18)14-3-13-5/h1-2,13-14H,3H2,(H2,12,15,16)
IUPAC Name
1,1-dioxo-6-(trifluoromethyl)-3,4-dihydro-2H-1λ⁶,2,4-benzothiadiazine-7-sulfonamide
SMILES
NS(=O)(=O)C1=CC2=C(NCNS2(=O)=O)C=C1C(F)(F)F
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzothiadiazines. These are organic compounds containing a benzene fused to a thiadiazine ring (a six-member ring with two nitrogen atoms and a sulfur atom).
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassThiadiazines
Sub ClassBenzothiadiazines
Direct ParentBenzothiadiazines
Alternative Parents
Substituents
  • Benzothiadiazine
  • Secondary aliphatic/aromatic amine
  • Benzenoid
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Azacycle
  • Secondary amine
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Amine
  • Alkyl halide
  • Alkyl fluoride
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationUsed as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Also used in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension.
PharmacodynamicsHydroflumethiazide is an oral thiazide used to treat hypertension and edema. High blood pressure adds to the workload of the heart and arteries. If it continues for a long time, the heart and arteries may not function properly. This can damage the blood vessels of the brain, heart, and kidneys, resulting in a stroke, heart failure, or kidney failure. High blood pressure may also increase the risk of heart attacks. Like other thiazides, Hydroflumethiazide promotes water loss from the body (diuretics). Thiazides inhibit Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity. Thiazides have been shown to prevent hypertension-related morbidity and mortality although the mechanism is not fully understood. Thiazides cause vasodilation by activating calcium-activated potassium channels (large conductance) in vascular smooth muscles and inhibiting various carbonic anhydrases in vascular tissue.
Mechanism of actionHydroflumethiazide is a thiazide diuretic that inhibits water reabsorption in the nephron by inhibiting the sodium-chloride symporter (SLC12A3) in the distal convoluted tubule, which is responsible for 5% of total sodium reabsorption. Normally, the sodium-chloride symporter transports sodium and chloride from the lumen into the epithelial cell lining the distal convoluted tubule. The energy for this is provided by a sodium gradient established by sodium-potassium ATPases on the basolateral membrane. Once sodium has entered the cell, it is transported out into the basolateral interstitium via the sodium-potassium ATPase, causing an increase in the osmolarity of the interstitium, thereby establishing an osmotic gradient for water reabsorption. By blocking the sodium-chloride symporter, Hydroflumethiazide effectively reduces the osmotic gradient and water reabsorption throughout the nephron.
Related Articles
AbsorptionHydroflumethiazide is incompletely but fairly rapidly absorbed from the gastrointestinal tract
Volume of distributionNot Available
Protein binding74%
Metabolism

Essentially unchanged

Route of eliminationNot Available
Half lifeIt appears to have a biphasic biological half-life with an estimated alpha-phase of about 2 hours and an estimated beta-phase of about 17 hours
ClearanceNot Available
ToxicityOverdoses lead to diuresis, lethargy progressing to coma, with minimal cardiorespiratory depression and with or without significant serum electrolyte changes or dehydration.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Hydroflumethiazide Action PathwayDrug actionSMP00108
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9636
Blood Brain Barrier-0.902
Caco-2 permeable-0.8221
P-glycoprotein substrateNon-substrate0.6668
P-glycoprotein inhibitor INon-inhibitor0.8016
P-glycoprotein inhibitor IINon-inhibitor0.787
Renal organic cation transporterNon-inhibitor0.8592
CYP450 2C9 substrateNon-substrate0.7732
CYP450 2D6 substrateNon-substrate0.8302
CYP450 3A4 substrateNon-substrate0.6442
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9232
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9544
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9324
Ames testNon AMES toxic0.8463
CarcinogenicityNon-carcinogens0.8011
BiodegradationNot ready biodegradable1.0
Rat acute toxicity3.1299 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9868
hERG inhibition (predictor II)Non-inhibitor0.8734
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Wyeth ayerst laboratories
  • Par pharmaceutical inc
  • Watson laboratories inc
  • Shire development inc
Packagers
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point272-273U.S. Patent 3,254,076.
water solubility300 mg/L (at 25 °C)MERCK INDEX (1996)
logP0.36HANSCH,C ET AL. (1995)
pKa8.9BUDAVARI,S ET AL. (1996)
Predicted Properties
PropertyValueSource
Water Solubility0.858 mg/mLALOGPS
logP0.44ALOGPS
logP-0.3ChemAxon
logS-2.6ALOGPS
pKa (Strongest Acidic)9.07ChemAxon
pKa (Strongest Basic)-2.7ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area118.36 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity64.28 m3·mol-1ChemAxon
Polarizability25.68 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

U.S. Patent 3,254,076.

General References
  1. Moser M, Feig PU: Fifty years of thiazide diuretic therapy for hypertension. Arch Intern Med. 2009 Nov 9;169(20):1851-6. doi: 10.1001/archinternmed.2009.342. [PubMed:19901136 ]
External Links
ATC CodesC03AB02C03AH02C03AA02
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
4-Androstenedione4-Androstenedione may increase the hypokalemic activities of Hydroflumethiazide.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Hydroflumethiazide.
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Hydroflumethiazide.
AcebutololHydroflumethiazide may increase the hypotensive activities of Acebutolol.
AceclofenacThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Aceclofenac.
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Hydroflumethiazide.
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Acetyldigitoxin.
Acetylsalicylic acidThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Acetylsalicylic acid.
AclidiniumThe serum concentration of Hydroflumethiazide can be increased when it is combined with Aclidinium.
AdapaleneThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Adapalene.
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Hydroflumethiazide.
AlclometasoneAlclometasone may increase the hypokalemic activities of Hydroflumethiazide.
AldosteroneAldosterone may increase the hypokalemic activities of Hydroflumethiazide.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Hydroflumethiazide.
AlfuzosinAlfuzosin may increase the hypotensive activities of Hydroflumethiazide.
AliskirenHydroflumethiazide may increase the hypotensive activities of Aliskiren.
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Hydroflumethiazide.
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Hydroflumethiazide.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Hydroflumethiazide.
AlprenololHydroflumethiazide may increase the hypotensive activities of Alprenolol.
AmbrisentanHydroflumethiazide may increase the hypotensive activities of Ambrisentan.
AmcinonideAmcinonide may increase the hypokalemic activities of Hydroflumethiazide.
AmifostineHydroflumethiazide may increase the hypotensive activities of Amifostine.
AmlodipineAmlodipine may increase the hypotensive activities of Hydroflumethiazide.
AmobarbitalAmobarbital may increase the orthostatic hypotensive activities of Hydroflumethiazide.
AmoxapineAmoxapine may increase the hyponatremic activities of Hydroflumethiazide.
Anisotropine MethylbromideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Anisotropine Methylbromide.
AntipyrineThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Antipyrine.
ApremilastThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Apremilast.
ArbutamineArbutamine may increase the hypokalemic activities of Hydroflumethiazide.
ArformoterolArformoterol may increase the hypokalemic activities of Hydroflumethiazide.
AtenololAtenolol may increase the hypotensive activities of Hydroflumethiazide.
Atracurium besylateThe serum concentration of Hydroflumethiazide can be increased when it is combined with Atracurium besylate.
AtropineThe serum concentration of Hydroflumethiazide can be increased when it is combined with Atropine.
AzapropazoneThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Azapropazone.
AzelastineThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Azelastine.
BalsalazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Balsalazide.
BambuterolBambuterol may increase the hypokalemic activities of Hydroflumethiazide.
BarbitalBarbital may increase the orthostatic hypotensive activities of Hydroflumethiazide.
Beclomethasone dipropionateBeclomethasone dipropionate may increase the hypokalemic activities of Hydroflumethiazide.
BenactyzineThe serum concentration of Hydroflumethiazide can be increased when it is combined with Benactyzine.
BenazeprilBenazepril may increase the hypotensive activities of Hydroflumethiazide.
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Hydroflumethiazide.
BenmoxinBenmoxin may increase the hypotensive activities of Hydroflumethiazide.
BenoxaprofenThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Benoxaprofen.
BenzatropineThe serum concentration of Hydroflumethiazide can be increased when it is combined with Benzatropine.
BepridilHydroflumethiazide may increase the hypotensive activities of Bepridil.
BetamethasoneBetamethasone may increase the hypokalemic activities of Hydroflumethiazide.
BetaxololBetaxolol may increase the hypotensive activities of Hydroflumethiazide.
BethanidineBethanidine may increase the hypotensive activities of Hydroflumethiazide.
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Hydroflumethiazide.
BimatoprostHydroflumethiazide may increase the hypotensive activities of Bimatoprost.
BiperidenThe serum concentration of Hydroflumethiazide can be increased when it is combined with Biperiden.
BisoprololBisoprolol may increase the hypotensive activities of Hydroflumethiazide.
BosentanBosentan may increase the hypotensive activities of Hydroflumethiazide.
BretyliumHydroflumethiazide may increase the hypotensive activities of Bretylium.
BrimonidineHydroflumethiazide may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Hydroflumethiazide.
BromfenacThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Bromfenac.
BudesonideBudesonide may increase the hypokalemic activities of Hydroflumethiazide.
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Hydroflumethiazide.
BupranololHydroflumethiazide may increase the hypotensive activities of Bupranolol.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Hydroflumethiazide.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Hydroflumethiazide.
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Hydroflumethiazide.
CandesartanHydroflumethiazide may increase the hypotensive activities of Candesartan.
CandoxatrilCandoxatril may increase the hypotensive activities of Hydroflumethiazide.
CaptoprilHydroflumethiazide may increase the hypotensive activities of Captopril.
CarbamazepineThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Carbamazepine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Hydroflumethiazide.
CaroxazoneCaroxazone may increase the hypotensive activities of Hydroflumethiazide.
CarprofenThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Carprofen.
CarteololCarteolol may increase the hypotensive activities of Hydroflumethiazide.
CarvedilolHydroflumethiazide may increase the hypotensive activities of Carvedilol.
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Hydroflumethiazide.
CelecoxibThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Celecoxib.
CeliprololHydroflumethiazide may increase the hypotensive activities of Celiprolol.
ChloroquineThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Chloroquine.
ChlorothiazideHydroflumethiazide may increase the hypotensive activities of Chlorothiazide.
ChlorphenoxamineThe serum concentration of Hydroflumethiazide can be increased when it is combined with Chlorphenoxamine.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Hydroflumethiazide.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Hydroflumethiazide.
CholestyramineCholestyramine can cause a decrease in the absorption of Hydroflumethiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.
CiclesonideCiclesonide may increase the hypokalemic activities of Hydroflumethiazide.
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Hydroflumethiazide.
CilazaprilHydroflumethiazide may increase the hypotensive activities of Cilazapril.
CitalopramCitalopram may increase the hyponatremic activities of Hydroflumethiazide.
ClenbuterolClenbuterol may increase the hypokalemic activities of Hydroflumethiazide.
Clobetasol propionateClobetasol propionate may increase the hypokalemic activities of Hydroflumethiazide.
ClocortoloneClocortolone may increase the hypokalemic activities of Hydroflumethiazide.
ClomipramineClomipramine may increase the hyponatremic activities of Hydroflumethiazide.
ClonidineClonidine may increase the hypotensive activities of Hydroflumethiazide.
ClonixinThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Clonixin.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Hydroflumethiazide.
ColesevelamColesevelam can cause a decrease in the absorption of Hydroflumethiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Hydroflumethiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cortisone acetateCortisone acetate may increase the hypokalemic activities of Hydroflumethiazide.
CryptenamineHydroflumethiazide may increase the hypotensive activities of Cryptenamine.
CyclopentolateThe serum concentration of Hydroflumethiazide can be increased when it is combined with Cyclopentolate.
CyclophosphamideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Cyclophosphamide.
CyclothiazideCyclothiazide may increase the hypotensive activities of Hydroflumethiazide.
D-LimoneneThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with D-Limonene.
DapoxetineDapoxetine may increase the hyponatremic activities of Hydroflumethiazide.
DarifenacinThe serum concentration of Hydroflumethiazide can be increased when it is combined with Darifenacin.
DebrisoquinHydroflumethiazide may increase the hypotensive activities of Debrisoquin.
DehydroepiandrosteroneDehydroepiandrosterone may increase the hypokalemic activities of Hydroflumethiazide.
dehydroepiandrosterone sulfatedehydroepiandrosterone sulfate may increase the hypokalemic activities of Hydroflumethiazide.
DeserpidineHydroflumethiazide may increase the hypotensive activities of Deserpidine.
DeslanosideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Deslanoside.
DesloratadineThe serum concentration of Hydroflumethiazide can be increased when it is combined with Desloratadine.
DesoximetasoneDesoximetasone may increase the hypokalemic activities of Hydroflumethiazide.
Desoxycorticosterone acetateDesoxycorticosterone acetate may increase the hypokalemic activities of Hydroflumethiazide.
DexamethasoneDexamethasone may increase the hypokalemic activities of Hydroflumethiazide.
Dexamethasone isonicotinateDexamethasone isonicotinate may increase the hypokalemic activities of Hydroflumethiazide.
DexetimideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Dexetimide.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Hydroflumethiazide.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Hydroflumethiazide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Hydroflumethiazide.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Hydroflumethiazide.
DiazoxideDiazoxide may increase the hypotensive activities of Hydroflumethiazide.
DiazoxideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Diazoxide.
DiclofenacThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Diclofenac.
DicyclomineThe serum concentration of Hydroflumethiazide can be increased when it is combined with Dicyclomine.
DiflorasoneDiflorasone may increase the hypokalemic activities of Hydroflumethiazide.
DiflunisalThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Diflunisal.
DifluocortoloneDifluocortolone may increase the hypokalemic activities of Hydroflumethiazide.
DifluprednateDifluprednate may increase the hypokalemic activities of Hydroflumethiazide.
DigitoxinThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Digitoxin.
DigoxinThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Digoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Hydroflumethiazide.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Hydroflumethiazide.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Hydroflumethiazide.
DiltiazemDiltiazem may increase the hypotensive activities of Hydroflumethiazide.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Hydroflumethiazide.
DipivefrinDipivefrin may increase the hypokalemic activities of Hydroflumethiazide.
DobutamineDobutamine may increase the hypokalemic activities of Hydroflumethiazide.
DofetilideHydroflumethiazide may increase the QTc-prolonging activities of Dofetilide.
DorzolamideHydroflumethiazide may increase the hypotensive activities of Dorzolamide.
DoxazosinDoxazosin may increase the hypotensive activities of Hydroflumethiazide.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Hydroflumethiazide.
DroxicamThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Droxicam.
DroxidopaDroxidopa may increase the hypokalemic activities of Hydroflumethiazide.
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Hydroflumethiazide.
EfonidipineHydroflumethiazide may increase the hypotensive activities of Efonidipine.
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Hydroflumethiazide.
EnalaprilEnalapril may increase the hypotensive activities of Hydroflumethiazide.
EnalaprilatHydroflumethiazide may increase the hypotensive activities of Enalaprilat.
EphedraEphedra may increase the hypokalemic activities of Hydroflumethiazide.
EpinephrineEpinephrine may increase the hypokalemic activities of Hydroflumethiazide.
EpirizoleThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Epirizole.
EpoprostenolHydroflumethiazide may increase the hypotensive activities of Epoprostenol.
EprosartanHydroflumethiazide may increase the hypotensive activities of Eprosartan.
EquileninEquilenin may increase the hypokalemic activities of Hydroflumethiazide.
EquilinEquilin may increase the hypokalemic activities of Hydroflumethiazide.
EscitalopramEscitalopram may increase the hyponatremic activities of Hydroflumethiazide.
EstroneEstrone may increase the hypokalemic activities of Hydroflumethiazide.
EtanerceptThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Etanercept.
EthanolEthanol may increase the orthostatic hypotensive activities of Hydroflumethiazide.
EthopropazineThe serum concentration of Hydroflumethiazide can be increased when it is combined with Ethopropazine.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Hydroflumethiazide.
EtodolacThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Etodolac.
EtofenamateThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Etofenamate.
EtoperidoneEtoperidone may increase the hyponatremic activities of Hydroflumethiazide.
EtoricoxibThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Etoricoxib.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Hydroflumethiazide.
Evening primrose oilThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Evening primrose oil.
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Hydroflumethiazide.
exisulindThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with exisulind.
FelodipineHydroflumethiazide may increase the hypotensive activities of Felodipine.
FenbufenThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Fenbufen.
FenfluramineFenfluramine may increase the hyponatremic activities of Hydroflumethiazide.
FenoldopamHydroflumethiazide may increase the hypotensive activities of Fenoldopam.
FenoprofenThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Fenoprofen.
FenoterolFenoterol may increase the hypokalemic activities of Hydroflumethiazide.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Hydroflumethiazide.
FesoterodineThe serum concentration of Hydroflumethiazide can be increased when it is combined with Fesoterodine.
FloctafenineThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Floctafenine.
FludrocortisoneFludrocortisone may increase the hypokalemic activities of Hydroflumethiazide.
FlumethasoneFlumethasone may increase the hypokalemic activities of Hydroflumethiazide.
FlunisolideFlunisolide may increase the hypokalemic activities of Hydroflumethiazide.
FlunixinThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Flunixin.
Fluocinolone AcetonideFluocinolone Acetonide may increase the hypokalemic activities of Hydroflumethiazide.
FluocinonideFluocinonide may increase the hypokalemic activities of Hydroflumethiazide.
FluocortoloneFluocortolone may increase the hypokalemic activities of Hydroflumethiazide.
FluorometholoneFluorometholone may increase the hypokalemic activities of Hydroflumethiazide.
FluoxetineFluoxetine may increase the hyponatremic activities of Hydroflumethiazide.
FluprednideneFluprednidene may increase the hypokalemic activities of Hydroflumethiazide.
FluprednisoloneFluprednisolone may increase the hypokalemic activities of Hydroflumethiazide.
FlurandrenolideFlurandrenolide may increase the hypokalemic activities of Hydroflumethiazide.
FlurbiprofenThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Flurbiprofen.
Fluticasone furoateFluticasone furoate may increase the hypokalemic activities of Hydroflumethiazide.
Fluticasone PropionateFluticasone Propionate may increase the hypokalemic activities of Hydroflumethiazide.
FluvoxamineFluvoxamine may increase the hyponatremic activities of Hydroflumethiazide.
FormoterolFormoterol may increase the hypokalemic activities of Hydroflumethiazide.
FosinoprilFosinopril may increase the hypotensive activities of Hydroflumethiazide.
FurazolidoneFurazolidone may increase the hypotensive activities of Hydroflumethiazide.
Gallamine TriethiodideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Gallamine Triethiodide.
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Hydroflumethiazide.
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Hydroflumethiazide.
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Hydroflumethiazide.
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Hydroflumethiazide.
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Hydroflumethiazide.
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Hydroflumethiazide.
GlycopyrroniumThe serum concentration of Hydroflumethiazide can be increased when it is combined with Glycopyrronium.
GuanabenzGuanabenz may increase the hypotensive activities of Hydroflumethiazide.
GuanadrelGuanadrel may increase the hypotensive activities of Hydroflumethiazide.
GuanethidineHydroflumethiazide may increase the hypotensive activities of Guanethidine.
GuanfacineHydroflumethiazide may increase the hypotensive activities of Guanfacine.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Hydroflumethiazide.
HexamethoniumHydroflumethiazide may increase the hypotensive activities of Hexamethonium.
HexobarbitalHexobarbital may increase the orthostatic hypotensive activities of Hydroflumethiazide.
HMPL-004The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with HMPL-004.
HomatropineThe serum concentration of Hydroflumethiazide can be increased when it is combined with Homatropine.
HydracarbazineHydracarbazine may increase the hypotensive activities of Hydroflumethiazide.
HydralazineHydroflumethiazide may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideHydroflumethiazide may increase the hypotensive activities of Hydrochlorothiazide.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Hydroflumethiazide.
HydrocortisoneHydrocortisone may increase the hypokalemic activities of Hydroflumethiazide.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Hydroflumethiazide.
HyoscyamineThe serum concentration of Hydroflumethiazide can be increased when it is combined with Hyoscyamine.
IbuprofenThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Ibuprofen.
IbuproxamThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Ibuproxam.
IcatibantThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Icatibant.
IloprostIloprost may increase the hypotensive activities of Hydroflumethiazide.
IndacaterolIndacaterol may increase the hypokalemic activities of Hydroflumethiazide.
IndalpineIndalpine may increase the hyponatremic activities of Hydroflumethiazide.
IndapamideHydroflumethiazide may increase the hypotensive activities of Indapamide.
IndenololHydroflumethiazide may increase the hypotensive activities of Indenolol.
IndomethacinThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Indomethacin.
IndoprofenThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Indoprofen.
IndoraminHydroflumethiazide may increase the hypotensive activities of Indoramin.
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Hydroflumethiazide.
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Hydroflumethiazide.
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Hydroflumethiazide.
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Hydroflumethiazide.
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Hydroflumethiazide.
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Hydroflumethiazide.
Ipratropium bromideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Ipratropium bromide.
IproclozideIproclozide may increase the hypotensive activities of Hydroflumethiazide.
IproniazidIproniazid may increase the hypotensive activities of Hydroflumethiazide.
IrbesartanHydroflumethiazide may increase the hypotensive activities of Irbesartan.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Hydroflumethiazide.
IsoetarineIsoetarine may increase the hypokalemic activities of Hydroflumethiazide.
IsoprenalineIsoprenaline may increase the hypokalemic activities of Hydroflumethiazide.
IsoxicamThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Isoxicam.
IsradipineIsradipine may increase the hypotensive activities of Hydroflumethiazide.
IvabradineHydroflumethiazide may increase the arrhythmogenic activities of Ivabradine.
KebuzoneThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Kebuzone.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Hydroflumethiazide.
KetoprofenThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Ketoprofen.
KetorolacThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Ketorolac.
LabetalolLabetalol may increase the hypotensive activities of Hydroflumethiazide.
LacidipineHydroflumethiazide may increase the hypotensive activities of Lacidipine.
LatanoprostLatanoprost may increase the hypotensive activities of Hydroflumethiazide.
LeflunomideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Leflunomide.
LercanidipineLercanidipine may increase the hypotensive activities of Hydroflumethiazide.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Hydroflumethiazide.
LevomilnacipranLevomilnacipran may increase the hyponatremic activities of Hydroflumethiazide.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Hydroflumethiazide.
LicoriceLicorice may increase the hypokalemic activities of Hydroflumethiazide.
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Hydroflumethiazide.
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Hydroflumethiazide.
LisinoprilLisinopril may increase the hypotensive activities of Hydroflumethiazide.
LithiumHydroflumethiazide may decrease the excretion rate of Lithium which could result in a lower serum level and potentially a reduction in efficacy.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Hydroflumethiazide.
LofexidineHydroflumethiazide may increase the hypotensive activities of Lofexidine.
LornoxicamThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Lornoxicam.
LosartanLosartan may increase the hypotensive activities of Hydroflumethiazide.
LoxoprofenThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Loxoprofen.
Lu AA21004Lu AA21004 may increase the hyponatremic activities of Hydroflumethiazide.
LumiracoxibThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Lumiracoxib.
MacitentanHydroflumethiazide may increase the hypotensive activities of Macitentan.
Magnesium salicylateThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Magnesium salicylate.
ManidipineHydroflumethiazide may increase the hypotensive activities of Manidipine.
MasoprocolThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Masoprocol.
MebanazineMebanazine may increase the hypotensive activities of Hydroflumethiazide.
MecamylamineThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Mecamylamine.
MecamylamineMecamylamine may increase the hypotensive activities of Hydroflumethiazide.
Meclofenamic acidThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Meclofenamic acid.
MedrysoneMedrysone may increase the hypokalemic activities of Hydroflumethiazide.
Mefenamic acidThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Mefenamic acid.
MelengestrolMelengestrol may increase the hypokalemic activities of Hydroflumethiazide.
MeloxicamThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Meloxicam.
MesalazineThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Mesalazine.
MetamizoleThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Metamizole.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Hydroflumethiazide.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Hydroflumethiazide.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Hydroflumethiazide.
MethanthelineThe serum concentration of Hydroflumethiazide can be increased when it is combined with Methantheline.
MethohexitalMethohexital may increase the orthostatic hypotensive activities of Hydroflumethiazide.
MethyldopaHydroflumethiazide may increase the hypotensive activities of Methyldopa.
Methylene blueMethylene blue may increase the hypotensive activities of Hydroflumethiazide.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Hydroflumethiazide.
MethylphenobarbitalMethylphenobarbital may increase the orthostatic hypotensive activities of Hydroflumethiazide.
MethylprednisoloneMethylprednisolone may increase the hypokalemic activities of Hydroflumethiazide.
MetipranololHydroflumethiazide may increase the hypotensive activities of Metipranolol.
MetixeneThe serum concentration of Hydroflumethiazide can be increased when it is combined with Metixene.
MetolazoneMetolazone may increase the hypotensive activities of Hydroflumethiazide.
MetoprololMetoprolol may increase the hypotensive activities of Hydroflumethiazide.
MibefradilHydroflumethiazide may increase the hypotensive activities of Mibefradil.
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Hydroflumethiazide.
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Hydroflumethiazide.
MilnacipranMilnacipran may increase the hyponatremic activities of Hydroflumethiazide.
MinaprineMinaprine may increase the hypotensive activities of Hydroflumethiazide.
MinoxidilMinoxidil may increase the hypotensive activities of Hydroflumethiazide.
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Hydroflumethiazide.
MoclobemideMoclobemide may increase the hypotensive activities of Hydroflumethiazide.
MoexiprilMoexipril may increase the hypotensive activities of Hydroflumethiazide.
MolsidomineMolsidomine may increase the hypotensive activities of Hydroflumethiazide.
MometasoneMometasone may increase the hypokalemic activities of Hydroflumethiazide.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Hydroflumethiazide.
MoxonidineHydroflumethiazide may increase the hypotensive activities of Moxonidine.
Mycophenolate mofetilThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Mycophenolate mofetil.
Mycophenolic acidThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Mycophenolic acid.
N-butylscopolammonium bromideThe serum concentration of Hydroflumethiazide can be increased when it is combined with N-butylscopolammonium bromide.
NabumetoneThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Nabumetone.
NadololHydroflumethiazide may increase the hypotensive activities of Nadolol.
NaftifineThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Naftifine.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Hydroflumethiazide.
NaproxenThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Naproxen.
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Hydroflumethiazide.
NCX 4016The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with NCX 4016.
NebivololHydroflumethiazide may increase the hypotensive activities of Nebivolol.
NepafenacThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Nepafenac.
NialamideNialamide may increase the hypotensive activities of Hydroflumethiazide.
NicardipineNicardipine may increase the hypotensive activities of Hydroflumethiazide.
NicorandilHydroflumethiazide may increase the hypotensive activities of Nicorandil.
Niflumic AcidThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Niflumic Acid.
NiguldipineHydroflumethiazide may increase the hypotensive activities of Niguldipine.
NilvadipineHydroflumethiazide may increase the hypotensive activities of Nilvadipine.
NimesulideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Nimesulide.
NimodipineNimodipine may increase the hypotensive activities of Hydroflumethiazide.
NisoldipineNisoldipine may increase the hypotensive activities of Hydroflumethiazide.
NitrendipineHydroflumethiazide may increase the hypotensive activities of Nitrendipine.
NitroprussideNitroprusside may increase the hypotensive activities of Hydroflumethiazide.
NorepinephrineNorepinephrine may increase the hypokalemic activities of Hydroflumethiazide.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Hydroflumethiazide.
NVA237The serum concentration of Hydroflumethiazide can be increased when it is combined with NVA237.
ObinutuzumabHydroflumethiazide may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Hydroflumethiazide.
OlanzapineOlanzapine may increase the hyponatremic activities of Hydroflumethiazide.
OlmesartanOlmesartan may increase the hypotensive activities of Hydroflumethiazide.
OlodaterolOlodaterol may increase the hypokalemic activities of Hydroflumethiazide.
OlopatadineThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Olopatadine.
OlsalazineThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Olsalazine.
OmapatrilatHydroflumethiazide may increase the hypotensive activities of Omapatrilat.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Hydroflumethiazide.
OrciprenalineOrciprenaline may increase the hypokalemic activities of Hydroflumethiazide.
OrgoteinThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Orgotein.
OrphenadrineThe serum concentration of Hydroflumethiazide can be increased when it is combined with Orphenadrine.
OuabainThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Ouabain.
OxaprozinThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Oxaprozin.
OxcarbazepineThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Oxcarbazepine.
OxprenololHydroflumethiazide may increase the hypotensive activities of Oxprenolol.
OxybutyninThe serum concentration of Hydroflumethiazide can be increased when it is combined with Oxybutynin.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Hydroflumethiazide.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Hydroflumethiazide.
OxyphenbutazoneThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Oxyphenbutazone.
OxyphenoniumThe serum concentration of Hydroflumethiazide can be increased when it is combined with Oxyphenonium.
PancuroniumThe serum concentration of Hydroflumethiazide can be increased when it is combined with Pancuronium.
ParamethasoneParamethasone may increase the hypokalemic activities of Hydroflumethiazide.
ParecoxibThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Parecoxib.
PargylineHydroflumethiazide may increase the hypotensive activities of Pargyline.
ParoxetineParoxetine may increase the hyponatremic activities of Hydroflumethiazide.
PenbutololHydroflumethiazide may increase the hypotensive activities of Penbutolol.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Hydroflumethiazide.
PentobarbitalPentobarbital may increase the orthostatic hypotensive activities of Hydroflumethiazide.
PentoliniumHydroflumethiazide may increase the hypotensive activities of Pentolinium.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Hydroflumethiazide.
PerindoprilHydroflumethiazide may increase the hypotensive activities of Perindopril.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Hydroflumethiazide.
PhenelzinePhenelzine may increase the hypotensive activities of Hydroflumethiazide.
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Hydroflumethiazide.
PheniprazinePheniprazine may increase the hypotensive activities of Hydroflumethiazide.
PhenobarbitalPhenobarbital may increase the orthostatic hypotensive activities of Hydroflumethiazide.
PhenoxybenzamineHydroflumethiazide may increase the hypotensive activities of Phenoxybenzamine.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Hydroflumethiazide.
PhentolaminePhentolamine may increase the hypotensive activities of Hydroflumethiazide.
PhenylbutazoneThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Phenylbutazone.
PhenylpropanolaminePhenylpropanolamine may increase the hypokalemic activities of Hydroflumethiazide.
PimecrolimusThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Pimecrolimus.
PinacidilHydroflumethiazide may increase the hypotensive activities of Pinacidil.
PindololHydroflumethiazide may increase the hypotensive activities of Pindolol.
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Hydroflumethiazide.
PipecuroniumThe serum concentration of Hydroflumethiazide can be increased when it is combined with Pipecuronium.
PirbuterolPirbuterol may increase the hypokalemic activities of Hydroflumethiazide.
PirenzepineThe serum concentration of Hydroflumethiazide can be increased when it is combined with Pirenzepine.
PirfenidoneThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Pirfenidone.
PirlindolePirlindole may increase the hypotensive activities of Hydroflumethiazide.
PiroxicamThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Piroxicam.
PivhydrazinePivhydrazine may increase the hypotensive activities of Hydroflumethiazide.
PolythiazideHydroflumethiazide may increase the hypotensive activities of Polythiazide.
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Hydroflumethiazide.
PrazosinPrazosin may increase the hypotensive activities of Hydroflumethiazide.
PrednicarbatePrednicarbate may increase the hypokalemic activities of Hydroflumethiazide.
PrednisolonePrednisolone may increase the hypokalemic activities of Hydroflumethiazide.
PrednisonePrednisone may increase the hypokalemic activities of Hydroflumethiazide.
PregnenolonePregnenolone may increase the hypokalemic activities of Hydroflumethiazide.
PrimidonePrimidone may increase the orthostatic hypotensive activities of Hydroflumethiazide.
ProcaterolProcaterol may increase the hypokalemic activities of Hydroflumethiazide.
ProcyclidineThe serum concentration of Hydroflumethiazide can be increased when it is combined with Procyclidine.
PropacetamolThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Propacetamol.
PropanthelineThe serum concentration of Hydroflumethiazide can be increased when it is combined with Propantheline.
PropranololPropranolol may increase the hypotensive activities of Hydroflumethiazide.
PTC299The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with PTC299.
QuinaprilHydroflumethiazide may increase the hypotensive activities of Quinapril.
QuinidineThe serum concentration of Hydroflumethiazide can be increased when it is combined with Quinidine.
QuinineQuinine may increase the hypotensive activities of Hydroflumethiazide.
RamiprilRamipril may increase the hypotensive activities of Hydroflumethiazide.
RasagilineRasagiline may increase the hypotensive activities of Hydroflumethiazide.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Hydroflumethiazide.
RemikirenRemikiren may increase the hypotensive activities of Hydroflumethiazide.
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Hydroflumethiazide.
RescinnamineHydroflumethiazide may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Hydroflumethiazide.
ResveratrolThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Resveratrol.
RimexoloneRimexolone may increase the hypokalemic activities of Hydroflumethiazide.
RiociguatHydroflumethiazide may increase the hypotensive activities of Riociguat.
RitodrineRitodrine may increase the hypokalemic activities of Hydroflumethiazide.
RituximabHydroflumethiazide may increase the hypotensive activities of Rituximab.
RofecoxibThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Rofecoxib.
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Hydroflumethiazide.
SafrazineSafrazine may increase the hypotensive activities of Hydroflumethiazide.
SalbutamolSalbutamol may increase the hypokalemic activities of Hydroflumethiazide.
SalicylamideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Salicylamide.
Salicylic acidThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Salicylic acid.
SalmeterolSalmeterol may increase the hypokalemic activities of Hydroflumethiazide.
SalsalateThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Salsalate.
SaprisartanHydroflumethiazide may increase the hypotensive activities of Saprisartan.
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Hydroflumethiazide.
ScopolamineThe serum concentration of Hydroflumethiazide can be increased when it is combined with Scopolamine.
Scopolamine butylbromideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Scopolamine butylbromide.
SecobarbitalSecobarbital may increase the orthostatic hypotensive activities of Hydroflumethiazide.
SelegilineSelegiline may increase the hypotensive activities of Hydroflumethiazide.
SelexipagHydroflumethiazide may increase the hypotensive activities of Selexipag.
SeratrodastThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Seratrodast.
SertralineSertraline may increase the hyponatremic activities of Hydroflumethiazide.
SildenafilSildenafil may increase the antihypertensive activities of Hydroflumethiazide.
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Hydroflumethiazide.
SitaxentanHydroflumethiazide may increase the hypotensive activities of Sitaxentan.
SolifenacinThe serum concentration of Hydroflumethiazide can be increased when it is combined with Solifenacin.
SpiraprilHydroflumethiazide may increase the hypotensive activities of Spirapril.
SRT501The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with SRT501.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Hydroflumethiazide.
SulfasalazineThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Sulfasalazine.
SulindacThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Sulindac.
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Hydroflumethiazide.
SulpirideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Sulpiride.
SuprofenThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Suprofen.
TadalafilTadalafil may increase the antihypertensive activities of Hydroflumethiazide.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Hydroflumethiazide.
TelmisartanHydroflumethiazide may increase the hypotensive activities of Telmisartan.
TemocaprilHydroflumethiazide may increase the hypotensive activities of Temocapril.
TenoxicamThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Tenoxicam.
TepoxalinThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Tepoxalin.
TerbutalineTerbutaline may increase the hypokalemic activities of Hydroflumethiazide.
TeriflunomideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Teriflunomide.
TerlipressinHydroflumethiazide may increase the hypotensive activities of Terlipressin.
ThiamylalThiamylal may increase the orthostatic hypotensive activities of Hydroflumethiazide.
ThiopentalThiopental may increase the orthostatic hypotensive activities of Hydroflumethiazide.
Tiaprofenic acidThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Tiaprofenic acid.
TiboloneHydroflumethiazide may increase the hypotensive activities of Tibolone.
TicrynafenHydroflumethiazide may increase the hypotensive activities of Ticrynafen.
TimololTimolol may increase the hypotensive activities of Hydroflumethiazide.
TiotropiumThe serum concentration of Hydroflumethiazide can be increased when it is combined with Tiotropium.
TixocortolTixocortol may increase the hypokalemic activities of Hydroflumethiazide.
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Hydroflumethiazide.
TolazolineHydroflumethiazide may increase the hypotensive activities of Tolazoline.
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Hydroflumethiazide.
Tolfenamic AcidThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Tolfenamic Acid.
TolmetinThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Tolmetin.
ToloxatoneToloxatone may increase the hypotensive activities of Hydroflumethiazide.
TolterodineThe serum concentration of Hydroflumethiazide can be increased when it is combined with Tolterodine.
TopiramateHydroflumethiazide may increase the hypokalemic activities of Topiramate.
TorasemideTorasemide may increase the hypotensive activities of Hydroflumethiazide.
ToremifeneHydroflumethiazide may increase the hypercalcemic activities of Toremifene.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Hydroflumethiazide.
TrandolaprilTrandolapril may increase the hypotensive activities of Hydroflumethiazide.
TranilastThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Tranilast.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Hydroflumethiazide.
TranylcypromineTranylcypromine may increase the hypotensive activities of Hydroflumethiazide.
TravoprostTravoprost may increase the hypotensive activities of Hydroflumethiazide.
TrazodoneTrazodone may increase the hyponatremic activities of Hydroflumethiazide.
TreprostinilTreprostinil may increase the hypotensive activities of Hydroflumethiazide.
TriamcinoloneTriamcinolone may increase the hypokalemic activities of Hydroflumethiazide.
TrichlormethiazideHydroflumethiazide may increase the hypotensive activities of Trichlormethiazide.
TrihexyphenidylThe serum concentration of Hydroflumethiazide can be increased when it is combined with Trihexyphenidyl.
TrimazosinHydroflumethiazide may increase the hypotensive activities of Trimazosin.
TrimethaphanHydroflumethiazide may increase the hypotensive activities of Trimethaphan.
Trisalicylate-cholineThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Trisalicylate-choline.
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Hydroflumethiazide.
TropicamideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Tropicamide.
TrospiumThe serum concentration of Hydroflumethiazide can be increased when it is combined with Trospium.
TubocurarineThe serum concentration of Hydroflumethiazide can be increased when it is combined with Tubocurarine.
UdenafilUdenafil may increase the antihypertensive activities of Hydroflumethiazide.
UmeclidiniumThe serum concentration of Hydroflumethiazide can be increased when it is combined with Umeclidinium.
UnoprostoneHydroflumethiazide may increase the hypotensive activities of Unoprostone.
ValdecoxibThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Valdecoxib.
ValsartanValsartan may increase the hypotensive activities of Hydroflumethiazide.
VardenafilVardenafil may increase the antihypertensive activities of Hydroflumethiazide.
VecuroniumThe serum concentration of Hydroflumethiazide can be increased when it is combined with Vecuronium.
VilanterolVilanterol may increase the hypokalemic activities of Hydroflumethiazide.
VilazodoneVilazodone may increase the hyponatremic activities of Hydroflumethiazide.
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Hydroflumethiazide.
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Hydroflumethiazide.
VortioxetineVortioxetine may increase the hyponatremic activities of Hydroflumethiazide.
XylometazolineHydroflumethiazide may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Hydroflumethiazide.
ZaltoprofenThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Zaltoprofen.
ZileutonThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Zileuton.
ZimelidineZimelidine may increase the hyponatremic activities of Hydroflumethiazide.
ZomepiracThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Zomepirac.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Sodium:potassium:chloride symporter activity
Specific Function:
Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
Gene Name:
SLC12A1
Uniprot ID:
Q13621
Molecular Weight:
121449.13 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Reversible hydration of carbon dioxide. Can hydrates cyanamide to urea.
Gene Name:
CA1
Uniprot ID:
P00915
Molecular Weight:
28870.0 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. Bioorg Med Chem. 2009 Feb 1;17(3):1214-21. doi: 10.1016/j.bmc.2008.12.023. Epub 2008 Dec 24. [PubMed:19119014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Essential for bone resorption and osteoclast differentiation (By similarity). Reversible hydration of carbon dioxide. Can hydrate cyanamide to urea. Involved in the regulation of fluid secretion into the anterior chamber of the eye. Contributes to intracellular pH regulation in the duodenal upper villous epithelium during proton-coupled peptide absorption. Stimulates the chloride-bicarbonate ex...
Gene Name:
CA2
Uniprot ID:
P00918
Molecular Weight:
29245.895 Da
References
  1. Schaeffer P, Vigne P, Frelin C, Lazdunski M: Identification and pharmacological properties of binding sites for the atypical thiazide diuretic, indapamide. Eur J Pharmacol. 1990 Jul 17;182(3):503-8. [PubMed:2226620 ]
  2. Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. Bioorg Med Chem. 2009 Feb 1;17(3):1214-21. doi: 10.1016/j.bmc.2008.12.023. Epub 2008 Dec 24. [PubMed:19119014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Reversible hydration of carbon dioxide. May stimulate the sodium/bicarbonate transporter activity of SLC4A4 that acts in pH homeostasis. It is essential for acid overload removal from the retina and retina epithelium, and acid release in the choriocapillaris in the choroid.
Gene Name:
CA4
Uniprot ID:
P22748
Molecular Weight:
35032.075 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. Bioorg Med Chem. 2009 Feb 1;17(3):1214-21. doi: 10.1016/j.bmc.2008.12.023. Epub 2008 Dec 24. [PubMed:19119014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Reversible hydration of carbon dioxide. Participates in pH regulation. May be involved in the control of cell proliferation and transformation. Appears to be a novel specific biomarker for a cervical neoplasia.
Gene Name:
CA9
Uniprot ID:
Q16790
Molecular Weight:
49697.36 Da
References
  1. Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. Bioorg Med Chem. 2009 Feb 1;17(3):1214-21. doi: 10.1016/j.bmc.2008.12.023. Epub 2008 Dec 24. [PubMed:19119014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Reversible hydration of carbon dioxide.
Gene Name:
CA12
Uniprot ID:
O43570
Molecular Weight:
39450.615 Da
References
  1. Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. Bioorg Med Chem. 2009 Feb 1;17(3):1214-21. doi: 10.1016/j.bmc.2008.12.023. Epub 2008 Dec 24. [PubMed:19119014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Steroid hormone binding
Specific Function:
This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates the electrochemical gradient of sodium and potassium ions, providing the energy for active transport of various nutrients.
Gene Name:
ATP1A1
Uniprot ID:
P05023
Molecular Weight:
112895.01 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Voltage-gated potassium channel activity
Specific Function:
Potassium channel activated by both membrane depolarization or increase in cytosolic Ca(2+) that mediates export of K(+). It is also activated by the concentration of cytosolic Mg(2+). Its activation dampens the excitatory events that elevate the cytosolic Ca(2+) concentration and/or depolarize the cell membrane. It therefore contributes to repolarization of the membrane potential. Plays a key ...
Gene Name:
KCNMA1
Uniprot ID:
Q12791
Molecular Weight:
137558.115 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23